# A Study of ATL1102 or Placebo in Participants With Non-ambulatory Duchenne Muscular Dystrophy

> **NCT05938023** · PHASE2 · TERMINATED · sponsor: **Percheron Therapeutics** · enrollment: 48 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** ATL1102 25mg
- **DRUG:** ATL1102 50mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05938023
- **Lead sponsor:** Percheron Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-05-18
- **Primary completion:** 2024-11-19
- **Final completion:** 2025-01-15
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** The study failed to meet its primary or secondary efficacy endpoints. In consultation with investigators, the sponsor determined that it is not in the best interests of patients for the study to continue.
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05938023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05938023, "A Study of ATL1102 or Placebo in Participants With Non-ambulatory Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05938023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*